Infectious Unenforceability

Infectious unenforceability is the doctrine that inequitable conduct in one patent's prosecution can render related patents in the same patent family unenforceable — even if those related patents are not independently tainted: EQUITABLE ORIGIN: inequitable conduct itself is an equitable defense rendering a patent unenforceable; infectious unenforceability extends this equitable remedy to prevent enforcement of related patents that benefited from or were connected to the misconduct; THERASENSE v. BECTON DICKINSON (Fed. Cir. 2011 en banc): the Federal Circuit substantially tightened the standards for both inequitable conduct and infectious unenforceability; before Therasense, 'plague-like' propagation of unenforceability across entire patent portfolios was common; Therasense raised the materiality threshold and demanded close nexus for infectious spread; PRE-THERASENSE HISTORY: courts had applied infectious unenforceability broadly; a single instance of misconduct in one application could infect dozens of continuation applications; patent owners faced catastrophic portfolio risk from one instance of inequitable conduct; POST-THERASENSE STANDARD: the Federal Circuit requires a closer, more specific connection between the misconduct in the infected patent and the tainted patent; the misconduct must have had some material effect on the related patent's prosecution, not merely a coincidental relationship; WHAT CONSTITUTES THE 'INFECTION': (1) the same undisclosed prior art that was withheld in the original prosecution was also withheld during prosecution of the related patent; (2) the prosecution of the related patent incorporated arguments, claim scope, or representations that depended on or were affected by the misconduct.

Therasense fundamentally restructured inequitable conduct analysis, with significant downstream effects on infectious unenforceability: THERASENSE v. BECTON DICKINSON, INC. (Fed. Cir. 2011 en banc): the court heightened both prongs of inequitable conduct — materiality and intent — in response to decades of overuse; MATERIALITY STANDARD (post-Therasense): the 'but-for' standard: the withheld reference or false statement must have been material to patentability — specifically, the USPTO would not have allowed the patent but-for the misconduct; EXCEPTION — AFFIRMATIVE EGREGIOUS MISCONDUCT: when the applicant engages in 'affirmative acts of egregious misconduct' (filing a false declaration, submitting misleading evidence), but-for materiality is not required; the materiality of the misconduct is presumed; INTENT STANDARD (post-Therasense): the intent to deceive must be the 'single most reasonable inference' from the evidence; if there are other plausible explanations for non-disclosure, the intent element is not met; EFFECT ON INFECTIOUS UNENFORCEABILITY: (1) by raising the underlying inequitable conduct bar so high, Therasense drastically reduced the number of cases where an underlying patent is found unenforceable — and thus limited the pool of cases where infectious unenforceability can even arise; (2) even when an underlying patent is found unenforceable, courts now require a stronger nexus between the misconduct and the related patent; (3) the doctrine is still alive but much harder to establish than before Therasense.

Courts look for a substantive, meaningful connection between the misconduct and the related patent before finding infectious unenforceability: CONNECTION FACTORS: (1) SAME UNDISCLOSED PRIOR ART: if the withheld prior art was also not disclosed during prosecution of related patents, and would have been material to those patents too, the infection spreads naturally; (2) RELATED CLAIMS: if the related patent's claims overlap significantly with or depend from the tainted patent's claims, the misconduct is more likely to have infected the related prosecution; (3) CONTINUATION RELATIONSHIP: continuation applications that claim priority to the tainted application share prosecution history; if the misleading information or undisclosed prior art was relevant to the continued prosecution, infection is more likely; (4) COMMON PROSECUTION COUNSEL: same prosecuting attorney handling both applications increases the inference that the misconduct was carried through; (5) TIMING: misconduct that occurred before or during prosecution of the related patent is more likely infecting than misconduct that post-dates the related prosecution; CASES WHERE INFECTION WAS FOUND: when the same false statement was submitted in multiple related patent applications; when a key prior art reference that was deliberately withheld from one application was also withheld from its continuation; CASES WHERE INFECTION WAS REJECTED: when the misconduct in Application A had no connection to the subject matter of Application B; when different art was relevant to different family members and the misconduct only affected one; when the related patent had independent prosecution merit apart from the misconduct.

Post-Therasense, the reach of infectious unenforceability is significantly limited compared to the pre-2011 era: PRE-THERASENSE BROAD SCOPE: before the 2011 Therasense decision, courts had rendered entire patent portfolios unenforceable based on a single instance of inequitable conduct; the 'plague doctrine' spread from any related patent to dozens of continuations; patent owners faced massive enforceability risk from isolated prosecution misconduct; POST-THERASENSE LIMITATION: Therasense signaled that courts should not propagate unenforceability without a strong nexus; 'close nexus' or 'but-for' connection between the specific misconduct and each related patent is required; the mere fact that two patents are in the same family is insufficient; PRACTICAL SCOPE TODAY: continuation directly from tainted application: high risk of infection if same art or same issues; divisional applications: lower risk if misconduct was specific to subject matter not covered by the divisional; continuation-in-part: infection may apply to claims that overlap with or depend on the original claims, but not to new matter claims that have independent support; ENTIRE PORTFOLIO: infecting an entire company's patent portfolio remains possible in egregious cases (e.g., systematic fraudulent prosecution across multiple applications) but is now exceptional; STRATEGIC CONSIDERATIONS: patent defendants still plead infectious unenforceability when inequitable conduct is found; the court will evaluate on a patent-by-patent basis; companies should conduct prosecution integrity audits to identify potential exposure across patent families; EXAMPLE — NARROWED INFECTION: if inequitable conduct occurred in Application A (claiming Feature X), a continuation B that also claims Feature X but adds Feature Y will likely be infected as to Feature X claims; B's claims directed solely to Feature Y may survive.

Infectious unenforceability is one of several prosecution-related patent defenses, but it operates differently from related doctrines: INFECTIOUS UNENFORCEABILITY: renders patents UNENFORCEABLE (no claims can be asserted); equitable defense; based on prosecutorial misconduct during USPTO prosecution; requires proving inequitable conduct in the predicate patent first; can spread to related patents based on nexus; PROSECUTION HISTORY ESTOPPEL: does NOT render a patent unenforceable; limits claim SCOPE — specifically narrows the doctrine of equivalents range for claim terms amended or argued during prosecution; Festo Corp. v. Shoketsu Kinzoku (S.Ct. 2002); applies to all patents based on their own prosecution history — not a 'spreading' doctrine; PATENT MISUSE: renders a patent unenforceable (like inequitable conduct); based on patent owner's ENFORCEMENT conduct (licensing terms, tying arrangements) rather than prosecution misconduct; can be 'purged' by ceasing the misuse and its effects; Morton Salt doctrine: patentee who extends patent scope beyond claims is misusing the patent; INEQUITABLE CONDUCT (PREDICATE): requires deliberate deception or withholding of material information during prosecution; if proven, renders the patent-in-suit unenforceable; may also infect related patents; COMPARING SEVERITY: inequitable conduct + infectious unenforceability = strongest equitable defense; can permanently bar enforcement across an entire patent family; prosecution history estoppel = limits scope but patent remains enforceable on its literal terms; patent misuse = temporary unenforceability, curable; SIMULTANEOUS ASSERTION: defendants typically assert all three where evidence supports them; courts address each separately.